Smith & Nephew Q1 sales hit by China weakness
Artificial knee and hip maker Smith & Nephew posted a 3% rise in first-quarter revenue, as a solid performance in the US was offset by weakness in China.
FTSE 100
8,071.19
16:49 14/11/24
FTSE 350
4,459.02
16:38 14/11/24
FTSE All-Share
4,417.25
16:54 14/11/24
Health Care Equipment & Services
10,406.99
16:38 14/11/24
Smith & Nephew
961.00p
16:40 14/11/24
For the quarter ended 2 April, revenue nudged up to $1.14bn from $1.10bn in the same period last year, which was below the $1.16bn expected by analysts. On an underlying basis, growth was 4%.
Revenue in the US grew 8%, but emerging markets saw a 6% decline, with double-digit growth in most countries offset by continued weakness in China and a significant slowdown in tendering and sales in oil-dependent Gulf States.
Established Markets saw revenue growth of 6%, which the company said reflected its success in the US and the sustained improvement it has made in Europe.
Revenue in Knee Implants was up 9%, boosted by strong sales of the Journey II Knee System, while Hip Implants saw 4% growth.
Chief executive officer Olivier Bohuon said: “Overall, we continue to expect good underlying revenue growth in 2016 as we benefit from our investments in existing businesses, acquisitions and pioneering technologies."